Empowered Patient Podcast

Colin Lawlor, CEO of Sleep ai, is focused on exploring sleep intelligence and sleep as a vital sign of health. The Sleep ai platform measures sleep longitudinally using data from consumer wearables and smartphones, with an emphasis on night-to-night variability, which is not captured in a single-night sleep lab. Poor sleep and variation in sleep patterns have been identified as highly predictive indicators of over 130 chronic diseases and have an impact on mental well-being and the effectiveness of medical treatments. Colin explains, "What we're doing is we're measuring sleep longitudinally, over the long term, and we're measuring it from whatever device the consumer has. For some consumers or patients, it may be wearable, and there are many, many different wearables, or for others, it's simply from their phone. We have the ability to collect high-quality sleep data from everyone every day. And that's really important because when we get into this, we'll talk about why longitudinal measurement is really helpful in dealing with sleep challenges themselves, but also in seeing sleep as a window into literally everything to do with our health."   "There are several factors going on here. The first one is that globally, four billion people wake up tired almost every day. We do not have, and we will never have, a sufficient number of sleep labs to send all of them for a one-night study. And if we collect data for only one night, we're only getting one picture of how that person is sleeping. But as we all know, life gets in the way. We may have had a stressful day, or we may have had an argument with our significant other. We may be suffering from a cold."   "Whatever it is, all of these multiple factors influence sleep. So if we over-rely on one data point to understand what's going on, it's just not sufficient. So what we are finding is that, actually, the variance night to night is probably the most useful and insightful thing we can see. Because when we look at the variance across many nights, we have a much more accurate picture of what's happening with the person's sleep, and that's highly predictive of many, many other conditions, issues, and challenges."  #SleepAI #DigitalHealth #SleepAsAVitalSign #ChronicDisease #PopulationHealth #AIinHealthcare #Wearables #LongitudinalData #SleepHealth, #SleepScience  sleep.ai Listen to the podcast here

Colin Lawlor, CEO of Sleep ai, is focused on exploring sleep intelligence and sleep as a vital sign of health. The Sleep ai platform measures sleep longitudinally using data from consumer wearables and smartphones, with an emphasis on night-to-night variability, which is not captured in a single-night sleep lab. Poor sleep and variation in sleep patterns have been identified as highly predictive indicators of over 130 chronic diseases and have an impact on mental well-being and the effectiveness of medical treatments. Colin explains, "What we're doing is we're measuring sleep longitudinally, over the long term, and we're measuring it from whatever device the consumer has. For some consumers or patients, it may be wearable, and there are many, many different wearables, or for others, it's simply from their phone. We have the ability to collect high-quality sleep data from everyone every day. And that's really important because when we get into this, we'll talk about why longitudinal measurement is really helpful in dealing with sleep challenges themselves, but also in seeing sleep as a window into literally everything to do with our health."   "There are several factors going on here. The first one is that globally, four billion people wake up tired almost every day. We do not have, and we will never have, a sufficient number of sleep labs to send all of them for a one-night study. And if we collect data for only one night, we're only getting one picture of how that person is sleeping. But as we all know, life gets in the way. We may have had a stressful day, or we may have had an argument with our significant other. We may be suffering from a cold."   "Whatever it is, all of these multiple factors influence sleep. So if we over-rely on one data point to understand what's going on, it's just not sufficient. So what we are finding is that, actually, the variance night to night is probably the most useful and insightful thing we can see. Because when we look at the variance across many nights, we have a much more accurate picture of what's happening with the person's sleep, and that's highly predictive of many, many other conditions, issues, and challenges."  #SleepAI #DigitalHealth #SleepAsAVitalSign #ChronicDisease #PopulationHealth #AIinHealthcare #Wearables #LongitudinalData #SleepHealth, #SleepScience  sleep.ai Download the transcript here

Zach Wood, Chief Product and Strategy Officer at Artera, and Meg Jackson, Director of IT for Beauregard Health Systems, join to discuss patient engagement in a rural healthcare setting that previously relied on minimal patient communication, relying on phone calls. The introduction of two-way texting has increased patient engagement, streamlined appointment scheduling, and improved medication adherence.  In communities with fewer landlines and limited broadband and computers, this secure texting solution is easy to use and available on patients' mobile devices for convenient access and an effective way to supplement in person care. Zach explains, "Artera works with a very broad set of provider organizations, ranging from specialty clinics to health systems to even federal agencies. We have about a thousand customers that we serve and have organizations like Beauregard that partner with us very closely in rural environments."   Meg elaborates, "We may have had some phone calls going out to patients before Artera, but no text reminder. So this was a brand new world for us. We wanted to bring more to the text message, to the patient on their personal devices. We live in a rural area, so maybe broadband is less accessible in our area. So we were trying to bring something to their devices for the patient." "Well, everyone today has a cell phone. Not everyone has a computer. A lot of people don't even have home phones anymore. So we wanted to get that as a text message to the patient, where they could just respond to it. The beauty of Artera, which first drew me to Artera, was the two-way communication. The patient can initiate the conversation without ever having been a patient here before. They can text the main number of our facility and start a conversation, and we can even have different rules set up on the Artera side, where it could trigger a certain conversation based on the patient's keywords. So that really empowers us to make it more customizable for our patient communication." #Artera #BeauregardHealthSystem #DrFirst #EmpoweredPatient #MedicationAdherence #HealthEquity #RuralHealth #HealthcareInnovation #PatientEngagement #DigitalHealth #RuralHealth #PatientExperience #HealthIT #SecureMessaging Artera.io Beauregard.org Listen to the podcast here

Zach Wood, Chief Product and Strategy Officer at Artera, and Meg Jackson, Director of IT for Beauregard Health Systems, join to discuss patient engagement in a rural healthcare setting that previously relied on minimal patient communication, relying on phone calls. The introduction of two-way texting has increased patient engagement, streamlined appointment scheduling, and improved medication adherence.  In communities with fewer landlines and limited broadband and computers, this secure texting solution is easy to use and available on patients' mobile devices for convenient access and an effective way to supplement in person care. Zach explains, "Artera works with a very broad set of provider organizations, ranging from specialty clinics to health systems to even federal agencies. We have about a thousand customers that we serve and have organizations like Beauregard that partner with us very closely in rural environments."   Meg elaborates, "We may have had some phone calls going out to patients before Artera, but no text reminder. So this was a brand new world for us. We wanted to bring more to the text message, to the patient on their personal devices. We live in a rural area, so maybe broadband is less accessible in our area. So we were trying to bring something to their devices for the patient." "Well, everyone today has a cell phone. Not everyone has a computer. A lot of people don't even have home phones anymore. So we wanted to get that as a text message to the patient, where they could just respond to it. The beauty of Artera, which first drew me to Artera, was the two-way communication. The patient can initiate the conversation without ever having been a patient here before. They can text the main number of our facility and start a conversation, and we can even have different rules set up on the Artera side, where it could trigger a certain conversation based on the patient's keywords. So that really empowers us to make it more customizable for our patient communication." #Artera #BeauregardHealthSystem #DrFirst #EmpoweredPatient #MedicationAdherence #HealthEquity #RuralHealth #HealthcareInnovation #PatientEngagement #DigitalHealth #RuralHealth #PatientExperience #HealthIT #SecureMessaging Artera.io Beauregard.org Download the transcript here

John D'Alesandro, a healthcare operations guru, Amplefi stresses that generally, healthcare operations do not suffer from a lack of staff or technology but from a failure to properly define goals and understand healthcare as a complex system. The reliance on outdated processes and the misapplication of technology has led to the introduction of AI into the environment without first addressing foundational system flaws. He advocates for a simpler, common-sense approach rather than platitudes about patient safety, ensuring that AI models are not trained on inaccurate data from broken systems or undocumented workarounds. John asks, "What is healthcare? Well, healthcare is a ton of things. What is the patient experience? Well, depends on the patient. So when we use these generic terms, they tend to cloud the performance of the system. So I think the first place we need to start is to say something like, " What's an ER experience that we're proud of?" If it's four hours, then it's four hours. But if it's longer or shorter than that, we need targets and reference models to know what we're doing, because we're adding a lot of things and a lot of complexity. We're not really realizing that those are systems. Those systems, when they produce friction, get hit on the frontline. The front lines have to deal with vague, unclear expectations."   "Patient experience isn't smiling. It's delivering your care in a reliable way. People get frustrated because they sit around waiting and wondering what the heck's going on. So I think just spending a little bit of time defining everything in your hospital, because every hospital's different." #Amplefi #DigitalHealth #PatientExperience #HealthcareInnovation #ConnectedHealth #PrecisionMedicine #HealthcareOperations #WorkflowDesign#OperationalExcellence #HealthcareSystems #FixTheProcess #BeforeCareBreaks #StructureMatters #ProcessOverTools #StopScalingChaos #HealthcareOperations #HospitalWorkflow #ClinicianBurnout #HealthSystems #AIinHealthcare #Telehealth #CareCoordination amplefi.com Listen to the podcast here

John D'Alesandro, a healthcare operations guru, Amplefi stresses that generally, healthcare operations do not suffer from a lack of staff or technology but from a failure to properly define goals and understand healthcare as a complex system. The reliance on outdated processes and the misapplication of technology has led to the introduction of AI into the environment without first addressing foundational system flaws. He advocates for a simpler, common-sense approach rather than platitudes about patient safety, ensuring that AI models are not trained on inaccurate data from broken systems or undocumented workarounds. John asks, "What is healthcare? Well, healthcare is a ton of things. What is the patient experience? Well, depends on the patient. So when we use these generic terms, they tend to cloud the performance of the system. So I think the first place we need to start is to say something like, " What's an ER experience that we're proud of?" If it's four hours, then it's four hours. But if it's longer or shorter than that, we need targets and reference models to know what we're doing, because we're adding a lot of things and a lot of complexity. We're not really realizing that those are systems. Those systems, when they produce friction, get hit on the frontline. The front lines have to deal with vague, unclear expectations."   "Patient experience isn't smiling. It's delivering your care in a reliable way. People get frustrated because they sit around waiting and wondering what the heck's going on. So I think just spending a little bit of time defining everything in your hospital, because every hospital's different." #Amplefi #DigitalHealth #PatientExperience #HealthcareInnovation #ConnectedHealth #PrecisionMedicine #HealthcareOperations #WorkflowDesign#OperationalExcellence #HealthcareSystems #FixTheProcess #BeforeCareBreaks #StructureMatters #ProcessOverTools #StopScalingChaos #HealthcareOperations #HospitalWorkflow #ClinicianBurnout #HealthSystems #AIinHealthcare #Telehealth #CareCoordination amplefi.com Download the transcript here

Ilana Golant, Founder and CEO of the Food Allergy Fund, discusses the increasing prevalence and complexity of food allergies in people of all ages and the lack of research, funding, and diagnostics in this field. The Food Allergy Fund is taking a multifaceted approach to address these challenges, including funding microbiome research, exploring drug repurposing, and leveraging AI to develop better diagnostic tools.  The goal is to find a cure for food allergies to prevent life-threatening anaphylaxis and drive research into the connection between food allergies and gut and immune health. Ilana explains, "We launched a microbiome research collective recently because we really think the microbiome is the common denominator for many diseases. I mean, food allergy really no longer exists in isolation. It used to be 20 years ago, you would say someone had a peanut allergy. That patient doesn't really exist anymore. It is estimated that 40% of patients who have food allergies also have asthma, which is a significant comorbidity, but their other diseases overlap with Crohn's, juvenile diabetes, and atopic dermatitis, among others."   "We really think of food allergy as the canary in the coal mine for lifelong gut and immune health, and what the microbiome dysregulation could mean not only for food allergy, but for broader gut health. And so as part of our Microbiome Collective, we're right now funding studies at six different research institutions across the country to try to figure out what this gut dysbiosis means for food allergy and much more." #FoodAllergyFund #FoodAllergyResearch #FoodAllergyAwareness #Biotech #Immunology #PatientAdvocacy #HealthcareInnovation #FoodAllergy #Microbiome #AIinHealthcare #DrugRepurposing #AllergyResearch #Anaphylaxis #PrecisionMedicine #EmpoweredPatient foodallergyfund.org  Listen to the podcast here

Ilana Golant, Founder and CEO of the Food Allergy Fund, discusses the increasing prevalence and complexity of food allergies in people of all ages and the lack of research, funding, and diagnostics in this field. The Food Allergy Fund is taking a multifaceted approach to address these challenges, including funding microbiome research, exploring drug repurposing, and leveraging AI to develop better diagnostic tools.  The goal is to find a cure for food allergies to prevent life-threatening anaphylaxis and drive research into the connection between food allergies and gut and immune health. Ilana explains, "We launched a microbiome research collective recently because we really think the microbiome is the common denominator for many diseases. I mean, food allergy really no longer exists in isolation. It used to be 20 years ago, you would say someone had a peanut allergy. That patient doesn't really exist anymore. It is estimated that 40% of patients who have food allergies also have asthma, which is a significant comorbidity, but their other diseases overlap with Crohn's, juvenile diabetes, and atopic dermatitis, among others."   "We really think of food allergy as the canary in the coal mine for lifelong gut and immune health, and what the microbiome dysregulation could mean not only for food allergy, but for broader gut health. And so as part of our Microbiome Collective, we're right now funding studies at six different research institutions across the country to try to figure out what this gut dysbiosis means for food allergy and much more." #FoodAllergyFund #FoodAllergyResearch #FoodAllergyAwareness #Biotech #Immunology #PatientAdvocacy #HealthcareInnovation #FoodAllergy #Microbiome #AIinHealthcare #DrugRepurposing #AllergyResearch #Anaphylaxis #PrecisionMedicine #EmpoweredPatient foodallergyfund.org Download the transcript here

Talia Cohen Solal, CEO and Co-Founder of NeuroKaire, is focused on improving patient outcomes of those with depression by predicting the most effective antidepressant for each individual. The NeuroKaire platform personalizes psychiatric treatment by creating neurons from a patient's blood sample to model their brain and test drug responses, pointing the way to an effective treatment, avoiding prolonged trial-and-error. This is a significant advancement over existing pharmacogenomic tests, which primarily provide information on drug metabolism rather than drug efficacy. This technology is also being applied to other conditions like ADHD, schizophrenia, bipolar disorder, and epilepsy.   Talia explains, "At NeuroKaire, we are dedicated to improving patient outcomes in psychiatry and neurology. To do that, we've developed a platform to predict which antidepressant is best for each patient and are expanding out to other disease indications to achieve that mission."   "Basically, around 2006, Yamanaka and his colleagues discovered that you could take any cell in the body and turn it back into a stem cell. And that changed everything for the field. So what we can do now is we can take a blood sample, turn it back into a stem cell, and then turn it into whatever cell type we'd like. And our mission is to help people with brain disorders and psychiatric disorders. And so we turn those stem cells into neurons. And now we have a model of the patient's brain. Now we have neurons from the patient's brain and a little ecosystem mimicking a patient's brain. And there we can actually see what's going wrong in the connectivity, what's changed in those patients, and what drugs are going to have the best outcome to reverse those changes." #NeuroKaire #PrecisionPsychiatry #MentalHealth #Antidepressants #BrightKaire #PersonalizedMedicine #PGx #Neuroscience #HealthcareInnovation neurokaire.com Listen to the podcast here

Talia Cohen Solal, CEO and Co-Founder of NeuroKaire, is focused on improving patient outcomes of those with depression by predicting the most effective antidepressant for each individual. The NeuroKaire platform personalizes psychiatric treatment by creating neurons from a patient's blood sample to model their brain and test drug responses, pointing the way to an effective treatment, avoiding prolonged trial-and-error. This is a significant advancement over existing pharmacogenomic tests, which primarily provide information on drug metabolism rather than drug efficacy. This technology is also being applied to other conditions like ADHD, schizophrenia, bipolar disorder, and epilepsy.   Talia explains, "At NeuroKaire, we are dedicated to improving patient outcomes in psychiatry and neurology. To do that, we've developed a platform to predict which antidepressant is best for each patient and are expanding out to other disease indications to achieve that mission."   "Basically, around 2006, Yamanaka and his colleagues discovered that you could take any cell in the body and turn it back into a stem cell. And that changed everything for the field. So what we can do now is we can take a blood sample, turn it back into a stem cell, and then turn it into whatever cell type we'd like. And our mission is to help people with brain disorders and psychiatric disorders. And so we turn those stem cells into neurons. And now we have a model of the patient's brain. Now we have neurons from the patient's brain and a little ecosystem mimicking a patient's brain. And there we can actually see what's going wrong in the connectivity, what's changed in those patients, and what drugs are going to have the best outcome to reverse those changes." #NeuroKaire #PrecisionPsychiatry #MentalHealth #Antidepressants #BrightKaire #PersonalizedMedicine #PGx #Neuroscience #HealthcareInnovation neurokaire.com Download the transcript here

Todd Van Meter, CEO of Accuity, highlights the evolution of the revenue cycle from simple billing and coding to include data analytics to reduce friction and prevent revenue leakage.  Accuity specializes in reviewing inpatient accounts before billing, using a combination of AI and physicians to ensure claims are compliant and accurate. Getting the clinical analysis and coding correct initially significantly reduces costly, time-consuming clinical denials.  Todd explains, Revenue cycle is a term that's really become more relevant here, in the last maybe decade plus. Years ago, it used to be called billing and coding and a whole different bunch of terms. And really, it's this whole idea of how, when a patient's going through their care event, how are you tracking them from when they access care all the way through documenting their care to coding the care they received and then getting a bill out to an insurance company or to a patient to get reimbursed for the care they received. And so the transformation has been going on for a long time."   "The cost has been pretty well identified over the years. From a cost perspective, the goal is to perform all of this work as cost-effectively as possible, and faster is better for patients and for hospitals in terms of processing accounts, cash flow, and other financial metrics. So I think what I've seen happening for health systems is that the data is allowing for better visibility, back to your cost point, into where there are opportunities to take out friction, to do things better, faster, cheaper, to process accounts. And to take care of patients better, and communicate better to both patients and insurance companies, and internally, just from a tracking perspective, and to make sure, to your other point, that there's really not any leakage all along the way." #Accuity #Healthcare #RevenueCycleManagement #RCM #Hospitals #InpatientCare #MedicalAI #HumanintheLoop accuityhealthcare.com Listen to the podcast here

Todd Van Meter, CEO of Accuity, highlights the evolution of the revenue cycle from simple billing and coding to include data analytics to reduce friction and prevent revenue leakage.  Accuity specializes in reviewing inpatient accounts before billing, using a combination of AI and physicians to ensure claims are compliant and accurate. Getting the clinical analysis and coding correct initially significantly reduces costly, time-consuming clinical denials.  Todd explains, Revenue cycle is a term that's really become more relevant here, in the last maybe decade plus. Years ago, it used to be called billing and coding and a whole different bunch of terms. And really, it's this whole idea of how, when a patient's going through their care event, how are you tracking them from when they access care all the way through documenting their care to coding the care they received and then getting a bill out to an insurance company or to a patient to get reimbursed for the care they received. And so the transformation has been going on for a long time."   "The cost has been pretty well identified over the years. From a cost perspective, the goal is to perform all of this work as cost-effectively as possible, and faster is better for patients and for hospitals in terms of processing accounts, cash flow, and other financial metrics. So I think what I've seen happening for health systems is that the data is allowing for better visibility, back to your cost point, into where there are opportunities to take out friction, to do things better, faster, cheaper, to process accounts. And to take care of patients better, and communicate better to both patients and insurance companies, and internally, just from a tracking perspective, and to make sure, to your other point, that there's really not any leakage all along the way." #Accuity #Healthcare #RevenueCycleManagement #RCM #Hospitals #InpatientCare #MedicalAI #HumanintheLoop accuityhealthcare.com Download the transcript here

Ewa and Doug Tweedy, and Dr. Nancy M. Young, the Lillian Wells Professor of Pediatric Otolaryngology at the Ann and Robert H. Lurie Children's Hospital in Chicago, come together to discuss bilateral sensorineural hearing loss. Nancy served as the principal investigator for a clinical trial examining the use of MED-EL's cochlear implants in young children with bilateral sensorineural hearing loss. Ewa and Doug's daughter, Ella, was born deaf in both ears and enrolled in the trial at seven months. The procedure and device have demonstrated safety and efficacy in supporting the development of listening and spoken language skills, with some surprising results. The Tweedy family emphasizes the importance of therapy and parental engagement in achieving positive outcomes, noting that Ella is excelling in a mainstream school.  Nancy explains, "Bilateral sensorineural hearing loss is permanent hearing loss. It arises from the inner ear. So we're not talking about temporary hearing loss from, say, fluid in the ear after a routine ear infection. So it usually arises from the inner ear, sometimes from the nerve of hearing. And it's often present at birth in certain children, but it can also have a later onset after birth." Ewa elaborates, "So, at the hospital right after her birth, we had someone come in to perform the newborn hearing screening, and we had two of those done one day after the next, and she did not pass either one of those. So they tried to tell us it might possibly be the fluid in the ears. So we just remained hopeful. But then, after a couple of weeks, we got her retested, again, and she did not pass. And then we went in for what Dr. Young referred to as the ADR so that diagnostic testing could be done for children. And there we found out that she did have the bilateral, so both sides, profound sensorineural hearing loss. We were told she was completely deaf." Doug continues, "I've had some passing information about it previously. I definitely was not an expert, definitely had not done the level of investigation and reading that I've done at this point. It was at least a familiarity to me. I do have a technologist background, so technology is something that has always been an interest to me, and cochlear implants are definitely a very unique technology." #MEDEL #CochlearImplants #Pediatrics #Audiology #ENT #EarlyIntervention #HearingHealth #SensorineuralHearingLoss #NeonatalCare #ChildDevelopment MEDEL.com Listen to the podcast here

Ewa and Doug Tweedy, and Dr. Nancy M. Young, the Lillian Wells Professor of Pediatric Otolaryngology at the Ann and Robert H. Lurie Children's Hospital in Chicago, come together to discuss bilateral sensorineural hearing loss. Nancy served as the principal investigator for a clinical trial examining the use of MED-EL's cochlear implants in young children with bilateral sensorineural hearing loss. Ewa and Doug's daughter, Ella, was born deaf in both ears and enrolled in the trial at seven months. The procedure and device have demonstrated safety and efficacy in supporting the development of listening and spoken language skills, with some surprising results. The Tweedy family emphasizes the importance of therapy and parental engagement in achieving positive outcomes, noting that Ella is excelling in a mainstream school.  Nancy explains, "Bilateral sensorineural hearing loss is permanent hearing loss. It arises from the inner ear. So we're not talking about temporary hearing loss from, say, fluid in the ear after a routine ear infection. So it usually arises from the inner ear, sometimes from the nerve of hearing. And it's often present at birth in certain children, but it can also have a later onset after birth." Ewa elaborates, "So, at the hospital right after her birth, we had someone come in to perform the newborn hearing screening, and we had two of those done one day after the next, and she did not pass either one of those. So they tried to tell us it might possibly be the fluid in the ears. So we just remained hopeful. But then, after a couple of weeks, we got her retested, again, and she did not pass. And then we went in for what Dr. Young referred to as the ADR so that diagnostic testing could be done for children. And there we found out that she did have the bilateral, so both sides, profound sensorineural hearing loss. We were told she was completely deaf." Doug continues, "I've had some passing information about it previously. I definitely was not an expert, definitely had not done the level of investigation and reading that I've done at this point. It was at least a familiarity to me. I do have a technologist background, so technology is something that has always been an interest to me, and cochlear implants are definitely a very unique technology." #MEDEL #CochlearImplants #Pediatrics #Audiology #ENT #EarlyIntervention #HearingHealth #SensorineuralHearingLoss #NeonatalCare #ChildDevelopment MEDEL.com Download the transcript here

Dr. Julie Chen, Chief Medical Officer at Radence, outlines the use of genomic precision medicine and advanced biomarkers and imaging technology for early detection and diagnosis of disease, with a focus on extending the health span, not just the lifespan, of their clients.  This comprehensive membership-based model aggregates members' health data to create a 360° view of their health risks. AI is a critical tool for identifying trends in longitudinal data, enabling more accurate and personalized health monitoring for both those who are healthy and those recovering from an existing condition. Julie explains, "Our model is a membership-based model primarily because a lot of the leading-edge technology is not insurance-covered. And so we're able to then utilize what is necessary for the diagnosis and the management, and actionable steps for the members, without having to worry about what insurance will or will not cover." "Our members come through, and we actually aggregate all of their outside medical records and data because we want to see what their baseline health has been up to the point that they join us as a member. And then at that point, we actually get from the cellular level all the way up to the organ level and functionality level, we start to aggregate information about their genomics, so the blueprint of who they are health-wise."   "The key focus here is really looking at the concept that longevity is a larger picture phrase that has been in this industry, used across the board for a lot of different things. That could encompass biohacking, to true evidence-based genomic precision medicine, to just trends of what people are using. So I think it's really important for your listeners to understand that longevity is theoretically in the category of what we're doing in that space, but the very important point is to really look at the space, as there are a lot of things on the market now."   #Radence #GenomicMedicine #PrecisionMedicine #EarlyDetection #HealthSpan #Longevity #AIinHealthcare #PreventiveCare  Radence.com Listen to the podcast here

Dr. Julie Chen, Chief Medical Officer at Radence, outlines the use of genomic precision medicine and advanced biomarkers and imaging technology for early detection and diagnosis of disease, with a focus on extending the health span, not just the lifespan, of their clients.  This comprehensive membership-based model aggregates members' health data to create a 360° view of their health risks. AI is a critical tool for identifying trends in longitudinal data, enabling more accurate and personalized health monitoring for both those who are healthy and those recovering from an existing condition. Julie explains, "Our model is a membership-based model primarily because a lot of the leading-edge technology is not insurance-covered. And so we're able to then utilize what is necessary for the diagnosis and the management, and actionable steps for the members, without having to worry about what insurance will or will not cover." "Our members come through, and we actually aggregate all of their outside medical records and data because we want to see what their baseline health has been up to the point that they join us as a member. And then at that point, we actually get from the cellular level all the way up to the organ level and functionality level, we start to aggregate information about their genomics, so the blueprint of who they are health-wise."   "The key focus here is really looking at the concept that longevity is a larger picture phrase that has been in this industry, used across the board for a lot of different things. That could encompass biohacking, to true evidence-based genomic precision medicine, to just trends of what people are using. So I think it's really important for your listeners to understand that longevity is theoretically in the category of what we're doing in that space, but the very important point is to really look at the space, as there are a lot of things on the market now."   #Radence #GenomicMedicine #PrecisionMedicine #EarlyDetection #HealthSpan #Longevity #AIinHealthcare #PreventiveCare  Radence.com Download the transcript here

Rick Focke, Director of Product and Market Development for Johnson Controls, focuses on AI's role in modernizing healthcare security and helping hospitals shift from reactive to proactive security. AI is improving staff efficiency, reducing nuisance alarms, detecting unauthorized wandering, and transforming cameras into multifaceted sensors for tasks such as fall detection and asset tracking, all without constant human monitoring. Of particular concern is the rise in workplace violence, and these cameras can detect aggressive behavior before incidents escalate. Rick explains, "Hospitals are a unique use case where they are in a very public space. So how do you secure a public space? You have to really weigh the security versus public areas and then keep the really sensitive areas safe and secure. And even though it might be mainly public spaces, keep a vigilant watch on those spaces. And we're using now a lot of AI to help in that task to really react quickly, to be proactive when things do go awry."   "The most unmet needs, I would say, would be being more proactive in the workplace violence area. It is really increasing from all the studies I've been reading. We need to do a better job of heading off in the pass. And that's where AI is really helping. With AI, you can train the system to detect bad behaviors or aggressive behaviors in patients, contractors, or anyone. When that happens, the system can alert the operators. They can send out different kinds of alerts based on how important it is, which really helps create a safer environment. We also have a lot of wearables that have person-down alerts when something happens that can reinforce that whole response when something is going awry." #JohnsonContols #HealthcareSecurity #HospitalSafety #AIinHealthcare #ClinicalSafety #WorkplaceViolencePrevention #PPECompliance #InfectionControl #SmartHospital #DigitalHealth #HealthIT #PatientSafety #HealthcareInnovation #OperationalExcellence johnsoncontrols.com Listen to the podcast here

Rick Focke, Director of Product and Market Development for Johnson Controls, focuses on AI's role in modernizing healthcare security and helping hospitals shift from reactive to proactive security. AI is improving staff efficiency, reducing nuisance alarms, detecting unauthorized wandering, and transforming cameras into multifaceted sensors for tasks such as fall detection and asset tracking, all without constant human monitoring. Of particular concern is the rise in workplace violence, and these cameras can detect aggressive behavior before incidents escalate. Rick explains, "Hospitals are a unique use case where they are in a very public space. So how do you secure a public space? You have to really weigh the security versus public areas and then keep the really sensitive areas safe and secure. And even though it might be mainly public spaces, keep a vigilant watch on those spaces. And we're using now a lot of AI to help in that task to really react quickly, to be proactive when things do go awry."   "The most unmet needs, I would say, would be being more proactive in the workplace violence area. It is really increasing from all the studies I've been reading. We need to do a better job of heading off in the pass. And that's where AI is really helping. With AI, you can train the system to detect bad behaviors or aggressive behaviors in patients, contractors, or anyone. When that happens, the system can alert the operators. They can send out different kinds of alerts based on how important it is, which really helps create a safer environment. We also have a lot of wearables that have person-down alerts when something happens that can reinforce that whole response when something is going awry." #JohnsonContols #HealthcareSecurity #HospitalSafety #AIinHealthcare #ClinicalSafety #WorkplaceViolencePrevention #PPECompliance #InfectionControl #SmartHospital #DigitalHealth #HealthIT #PatientSafety #HealthcareInnovation #OperationalExcellence johnsoncontrols.com Download the transcript here

Dr. Yana Aznavour, CEO and Founder of Endometrics, discusses the significant diagnostic delay women face with endometriosis due to non-specific symptoms and the current reliance on invasive surgery for a definitive diagnosis. The company has developed a non-invasive at-home diagnostic test that uses menstrual blood to analyze a five-gene biomarker signature with high accuracy.  This objective, molecular-based test shortens the time to the correct treatment and changes the dynamic of the patient-doctor conversation. Yana explains, "We are developing non-invasive diagnostic tests, and we are primarily addressing the huge diagnostic delay that our patients, women, face, unfortunately. This happens because there are tons of non-specific symptoms and inconclusive imaging findings, and women face unnecessary appointments and procedures before reaching the point of definitive diagnosis. We are working rigorously towards bringing non-invasive, highly reliable diagnostic tests to help women get clarity and answers behind their symptoms way earlier in the journey."   "Menstrual pain and pain in general that women try to express and define at physician's appointments, it's being dismissed because they try to explain that, but in many cases, they cannot find exactly where it hurts, especially in endometriosis. Due to this, unfortunately, at the primary care level and the non-OB/GYN level, they're being dismissed and repeatedly misdiagnosed for years. The key reason is the non-specific symptoms because symptoms like pelvic pain and pain with urination overlap with the list of diagnoses. Currently, the definitive diagnosis for endometriosis is achieved through surgery. Nobody would do surgery after the first appointment. So, endometriosis becomes a diagnosis of exclusion, unfortunately, and it takes years before patients receive the final diagnosis." #Endometrics #Endometriosis, #WomensHealth, #Biomarkers, #Diagnostics, #FemTech #Gynecology #PrecisionMedicine endometrics.us Listen to the podcast here

Dr. Yana Aznavour, CEO and Founder of Endometrics, discusses the significant diagnostic delay women face with endometriosis due to non-specific symptoms and the current reliance on invasive surgery for a definitive diagnosis. The company has developed a non-invasive at-home diagnostic test that uses menstrual blood to analyze a five-gene biomarker signature with high accuracy.  This objective, molecular-based test shortens the time to the correct treatment and changes the dynamic of the patient-doctor conversation. Yana explains, "We are developing non-invasive diagnostic tests, and we are primarily addressing the huge diagnostic delay that our patients, women, face, unfortunately. This happens because there are tons of non-specific symptoms and inconclusive imaging findings, and women face unnecessary appointments and procedures before reaching the point of definitive diagnosis. We are working rigorously towards bringing non-invasive, highly reliable diagnostic tests to help women get clarity and answers behind their symptoms way earlier in the journey."   "Menstrual pain and pain in general that women try to express and define at physician's appointments, it's being dismissed because they try to explain that, but in many cases, they cannot find exactly where it hurts, especially in endometriosis. Due to this, unfortunately, at the primary care level and the non-OB/GYN level, they're being dismissed and repeatedly misdiagnosed for years. The key reason is the non-specific symptoms because symptoms like pelvic pain and pain with urination overlap with the list of diagnoses. Currently, the definitive diagnosis for endometriosis is achieved through surgery. Nobody would do surgery after the first appointment. So, endometriosis becomes a diagnosis of exclusion, unfortunately, and it takes years before patients receive the final diagnosis." #Endometrics #Endometriosis, #WomensHealth, #Biomarkers, #Diagnostics, #FemTech #Gynecology #PrecisionMedicine endometrics.us Download the transcript here

Thomas Ruggia, CEO and President of Theialife,  delves into pediatric progressive myopia, a severe form of nearsightedness caused by the elongation of the eye in children, which can lead to significant long-term health issues.  The development of their novel oral therapy is designed to address the underlying physiology of the eye by strengthening the sclera to halt its elongation, unlike other treatments that only manage visual acuity. This oral therapy is available in capsules that can be opened and sprinkled on food, making it patient-friendly and child-compliant, avoiding the need for often hard-to-administer eye drops. Thomas explains, "Myopia is known as nearsightedness, and I think everybody is familiar with folks who wear spectacles for nearsightedness, or contact lenses, or have had LASIK surgery. But pediatric progressive myopia is a subset of myopia that is particularly difficult."  "The pediatric progressive myopia is a disease that's a bit different than just standard nearsightedness. Someone who might be minus two myopic can easily correct their vision with glasses. In this type of condition, generally, parents have a child who is having some difficulty seeing, and the next year, the child has extreme difficulty seeing. And then every year following, things get worse and worse. They end up at the optometrist or ophthalmologist for extensive recalculating their prescription, new glasses for those years of maybe between six and 16 years old."  "We're actually talking about a disorder that continues for the life of the patient that leads to significant challenges between the ages of, let's say, 40 and 80, where this elongated eye, which is what the condition really is, leads to challenges in retina detachment, maculopathy, early cataracts, and other conditions that are unique to the myopia patients."   "So we have a number of medical devices and pharmaceutical interventions that are being studied today, all of which have an effect on the visual acuity a patient might experience, but none of them affect the underlying structural changes in the eye during that time period. And our ND10 from Theialife has the potential to do so."  #Theialife  #MyopiaAwareness #PediatricMyopia #PediatricOphthalmology #VisionHealth #ND10 #AdenosineReceptors #7Methylxanthine #MyopiaManagement #Ophthalmology #Optometry #ChildEyeHealth #ScleralStrengthening #OphthalmicInnovation #EyeCare Theialife.com  Listen to the podcast here

Thomas Ruggia, CEO and President of Theialife,  delves into pediatric progressive myopia, a severe form of nearsightedness caused by the elongation of the eye in children, which can lead to significant long-term health issues.  The development of their novel oral therapy is designed to address the underlying physiology of the eye by strengthening the sclera to halt its elongation, unlike other treatments that only manage visual acuity. This oral therapy is available in capsules that can be opened and sprinkled on food, making it patient-friendly and child-compliant, avoiding the need for often hard-to-administer eye drops. Thomas explains, "Myopia is known as nearsightedness, and I think everybody is familiar with folks who wear spectacles for nearsightedness, or contact lenses, or have had LASIK surgery. But pediatric progressive myopia is a subset of myopia that is particularly difficult."  "The pediatric progressive myopia is a disease that's a bit different than just standard nearsightedness. Someone who might be minus two myopic can easily correct their vision with glasses. In this type of condition, generally, parents have a child who is having some difficulty seeing, and the next year, the child has extreme difficulty seeing. And then every year following, things get worse and worse. They end up at the optometrist or ophthalmologist for extensive recalculating their prescription, new glasses for those years of maybe between six and 16 years old."  "We're actually talking about a disorder that continues for the life of the patient that leads to significant challenges between the ages of, let's say, 40 and 80, where this elongated eye, which is what the condition really is, leads to challenges in retina detachment, maculopathy, early cataracts, and other conditions that are unique to the myopia patients."   "So we have a number of medical devices and pharmaceutical interventions that are being studied today, all of which have an effect on the visual acuity a patient might experience, but none of them affect the underlying structural changes in the eye during that time period. And our ND10 from Theialife has the potential to do so."  #Theialife #MyopiaAwareness #PediatricMyopia #PediatricOphthalmology #VisionHealth #ND10 #AdenosineReceptors #7Methylxanthine #MyopiaManagement #Ophthalmology #Optometry #ChildEyeHealth #ScleralStrengthening #OphthalmicInnovation #EyeCare Theialife.com Download the transcript here

Stephanie Broussard, Director of Social Work at Thyme Care, describes a model of interdisciplinary social support for cancer patients to increase access to medical services and address social, emotional, and financial challenges. Integrated services target family dynamics, social determinants of health, and building trust to drive better patient outcomes. As cancer increasingly becomes a chronic condition, there is a growing need to support the management of long-term physical and emotional effects and use technology to increase efficiency and support the Thyme Care human-focused approach. Stephanie explains, "Thyme Care is really designed to try to integrate and increase access for those navigating cancers. So we believe that in order to serve people really well, you don't take things away, you actually add things. If we can increase access and increase the ability for patients to navigate the health system, then we're able to better navigate their utilization. So we try to increase access through access to an interdisciplinary team. We have nurse practitioners, nurses, even oncologists and primary care physicians on our team, social workers, and lay people who help us make sure that patients can get what they need at the right time. And so it's really about giving patients access to the right services at the right time to improve their outcomes."   "We think about how their cancer impacts every facet of their life. And so, we often talk a lot about the financial toxicity of cancer, but social issues that were affecting folks don't just stop because cancer happened. Oftentimes, it even exacerbates those things. So think about family dynamics, think about social determinants of health, like the cost of medications and access, but also all the other things that can be impacted by cancer." #ThymeCare #ValueBasedCare #SocialWorkMonth #OncologySocialWork #MentalHealthMatters #CaregiverSupport #PatientExperience #HealthEquity #OncologyCare #ValueBasedCare #CareCoordination #SocialDeterminantsOfHealth #SDoH #CancerSurvivorship #Caregivers #NurseNavigation #PalliativeCare thymecare.com Listen to the podcast here  

Stephanie Broussard, Director of Social Work at Thyme Care, describes a model of interdisciplinary social support for cancer patients to increase access to medical services and address social, emotional, and financial challenges. Integrated services target family dynamics, social determinants of health, and building trust to drive better patient outcomes. As cancer increasingly becomes a chronic condition, there is a growing need to support the management of long-term physical and emotional effects and use technology to increase efficiency and support the Thyme Care human-focused approach. Stephanie explains, "Thyme Care is really designed to try to integrate and increase access for those navigating cancers. So we believe that in order to serve people really well, you don't take things away, you actually add things. If we can increase access and increase the ability for patients to navigate the health system, then we're able to better navigate their utilization. So we try to increase access through access to an interdisciplinary team. We have nurse practitioners, nurses, even oncologists and primary care physicians on our team, social workers, and lay people who help us make sure that patients can get what they need at the right time. And so it's really about giving patients access to the right services at the right time to improve their outcomes."   "We think about how their cancer impacts every facet of their life. And so, we often talk a lot about the financial toxicity of cancer, but social issues that were affecting folks don't just stop because cancer happened. Oftentimes, it even exacerbates those things. So think about family dynamics, think about social determinants of health, like the cost of medications and access, but also all the other things that can be impacted by cancer." #ThymeCare #ValueBasedCare #SocialWorkMonth #OncologySocialWork #MentalHealthMatters #CaregiverSupport #PatientExperience #HealthEquity #OncologyCare #ValueBasedCare #CareCoordination #SocialDeterminantsOfHealth #SDoH #CancerSurvivorship #Caregivers #NurseNavigation #PalliativeCare thymecare.com Download the transcript here

Dr. Stephanie Lahr, Chief Medical Officer at uPerform, highlights the critical need for new ways to conduct health IT education. Traditional one-time training sessions for large groups are no longer sufficient for the constantly evolving healthcare technologies. Self-paced and personalized training is the way to meet users at their individual skill levels, freeing up training teams to provide targeted support and build organizational competencies, including how to effectively use AI.  Stephanie explains, "This idea, which we are seeing evolve rapidly, is that as we integrate technology into healthcare delivery, people need to understand how to use it, which requires ongoing training, support, and communication."   "It's really a way to think about doing just-in-time, as-needed, self-driven education based on the user for whatever needs might arise with the technology they're using in care delivery. Often, that starts with systems like the EHR and ERP, but it goes far beyond that. And we're seeing that more and more as different kinds of technologies find their way into healthcare delivery to support the care providers in what they're trying to do."  "Traditionally, we had this idea that we rolled out technology, and you did some training, which usually involved a classroom, a quick video tutorial, or maybe an online course or something along those lines. And it was sort of a one-and-done: you learned it, you went, you moved on, and you used it. And I think what we're now seeing is that the systems themselves are changing constantly."   #uPerform #AI #JustInTimeTraining #WorkflowEducation #HealthIT #EHR #ClinicalInformatics #DigitalHealth #ClinicianExperience #HealthcareInnovation #MedicalEducation #AIinHealthcare uperform.com Listen to the podcast here

Dr. Stephanie Lahr, Chief Medical Officer at uPerform, highlights the critical need for new ways to conduct health IT education. Traditional one-time training sessions for large groups are no longer sufficient for the constantly evolving healthcare technologies. Self-paced and personalized training is the way to meet users at their individual skill levels, freeing up training teams to provide targeted support and build organizational competencies, including how to effectively use AI.  Stephanie explains, "This idea, which we are seeing evolve rapidly, is that as we integrate technology into healthcare delivery, people need to understand how to use it, which requires ongoing training, support, and communication."   "It's really a way to think about doing just-in-time, as-needed, self-driven education based on the user for whatever needs might arise with the technology they're using in care delivery. Often, that starts with systems like the EHR and ERP, but it goes far beyond that. And we're seeing that more and more as different kinds of technologies find their way into healthcare delivery to support the care providers in what they're trying to do."  "Traditionally, we had this idea that we rolled out technology, and you did some training, which usually involved a classroom, a quick video tutorial, or maybe an online course or something along those lines. And it was sort of a one-and-done: you learned it, you went, you moved on, and you used it. And I think what we're now seeing is that the systems themselves are changing constantly."   #uPerform #AI #JustInTimeTraining #WorkflowEducation #HealthIT #EHR #ClinicalInformatics #DigitalHealth #ClinicianExperience #HealthcareInnovation #MedicalEducation #AIinHealthcare uperform.com Download the transcript here

Dr. Ravi Kapur, Co-Founder and CEO of AutoIVF,  describes the current state of IVF as an expensive artisanal process with limited access due to structural constraints and a shortage of highly skilled embryologists. Bringing automation to the environment increases lab throughput and lowers costs, enabling a decentralized model where eggs are collected at an OB/GYN office. This data-driven technology can recover viable eggs that may have been discarded in the past, potentially improving success rates, greatly expanding access, and standardizing best practices across clinics.  Ravi explains, "Our mission is to expand access to fertility care by transforming IVF into a scalable, automated, and standardized platform. So the big picture goal here is to democratize IVF, enable affordable access to all patients who can benefit from IVF."   "Some of the big problems in IVF today are limited access and long wait times. This is in a demand-limited market. It's a supply-limited market, structurally constrained. Automation is going to enable increasing lab throughput. Automation will enable more cycles for the lab or embryologist, and automation enables uniquely meaningful, low-cost expansion into underserved regions."   "It's a very artisanal process. It requires a small pool of very highly skilled radiologists, and it takes years of training to get to that level of scale. What we aim to do is automate best practices into technology, which then drives standardized systems. And IVF is expensive. It's one of the key barriers to entry. It's $15,000 to $25,000 per cycle in the US and often requires multiple cycles to a live birth." #AutoIVF #Fertility #HealthcareInnovation #IVF #Automation #ReproductiveHealth #FertilityCare #DigitalHealth #MedTech #AutomationInHealthcare #ReproductiveMedicine #AccessToCare  AutoIVF.com Listen to the podcast here

Dr. Ravi Kapur, Co-Founder and CEO of AutoIVF,  describes the current state of IVF as an expensive artisanal process with limited access due to structural constraints and a shortage of highly skilled embryologists. Bringing automation to the environment increases lab throughput and lowers costs, enabling a decentralized model where eggs are collected at an OB/GYN office. This data-driven technology can recover viable eggs that may have been discarded in the past, potentially improving success rates, greatly expanding access, and standardizing best practices across clinics.  Ravi explains, "Our mission is to expand access to fertility care by transforming IVF into a scalable, automated, and standardized platform. So the big picture goal here is to democratize IVF, enable affordable access to all patients who can benefit from IVF."   "Some of the big problems in IVF today are limited access and long wait times. This is in a demand-limited market. It's a supply-limited market, structurally constrained. Automation is going to enable increasing lab throughput. Automation will enable more cycles for the lab or embryologist, and automation enables uniquely meaningful, low-cost expansion into underserved regions."   "It's a very artisanal process. It requires a small pool of very highly skilled radiologists, and it takes years of training to get to that level of scale. What we aim to do is automate best practices into technology, which then drives standardized systems. And IVF is expensive. It's one of the key barriers to entry. It's $15,000 to $25,000 per cycle in the US and often requires multiple cycles to a live birth." #AutoIVF #Fertility #HealthcareInnovation #IVF #Automation #ReproductiveHealth #FertilityCare #DigitalHealth #MedTech #AutomationInHealthcare #ReproductiveMedicine #AccessToCare  AutoIVF.com Download the transcript here

Greg Miller, VP of Marketing and Business Development at Carta Healthcare,  is focused on the multi-billion-dollar problem of manual clinical data abstraction in health systems, which is time-consuming, labor-intensive, and error-prone. The Carta hybrid intelligence solution combines AI  with human expertise to surface and validate information, delivering dramatic ROI for clients through lower costs and higher data quality. Clinician adoption grows significantly once they have experienced the AI finding information they would have missed, ultimately making them more effective at their jobs. Greg explains, "Health systems in the US, specifically, spend between $10 and $15 billion a year on manually abstracting data. And what are they abstracting data for? "There are lots of different downstream use cases, but the most common reason is to populate clinical registries. And clinical registries are super important because they're used for accreditation of clinical programs. It's for revenue, it's for compliance and regulatory requirements. But the biggest use of registry data is to drive quality and process improvement initiatives." "Unfortunately, today, every hospital has an abstraction function that is highly decentralized, and they have highly skilled labor, mostly nurses, who manually come through the electronic health record and other systems to find nuggets of information to answer questions in some registry system. And so it's very time-consuming, labor-intensive, and, because it involves humans, both expensive and prone to error."  #CartaHealthcare #HealthcareAI #HybridIntelligence #ClinicalAI #HealthTech #DigitalHealth #AIinHealthcare #LifeSciences #HealthData #AIgovernance #ResponsibleAI #ClinicalInnovation #HealthcareLeadership #HealthcareInnovation #ClinicalData #QualityImprovement #PatientSafety #DataAbstraction #HybridIntelligence carta.healthcare Listen to the podcast here

Greg Miller, VP of Marketing and Business Development at Carta Healthcare,  is focused on the multi-billion-dollar problem of manual clinical data abstraction in health systems, which is time-consuming, labor-intensive, and error-prone. The Carta hybrid intelligence solution combines AI  with human expertise to surface and validate information, delivering dramatic ROI for clients through lower costs and higher data quality. Clinician adoption grows significantly once they have experienced the AI finding information they would have missed, ultimately making them more effective at their jobs. Greg explains, "Health systems in the US, specifically, spend between $10 and $15 billion a year on manually abstracting data. And what are they abstracting data for? "There are lots of different downstream use cases, but the most common reason is to populate clinical registries. And clinical registries are super important because they're used for accreditation of clinical programs. It's for revenue, it's for compliance and regulatory requirements. But the biggest use of registry data is to drive quality and process improvement initiatives." "Unfortunately, today, every hospital has an abstraction function that is highly decentralized, and they have highly skilled labor, mostly nurses, who manually come through the electronic health record and other systems to find nuggets of information to answer questions in some registry system. And so it's very time-consuming, labor-intensive, and, because it involves humans, both expensive and prone to error."  #CartaHealthcare #HealthcareAI #HybridIntelligence #ClinicalAI #HealthTech #DigitalHealth #AIinHealthcare #LifeSciences #HealthData #AIgovernance #ResponsibleAI #ClinicalInnovation #HealthcareLeadership #HealthcareInnovation #ClinicalData #QualityImprovement #PatientSafety #DataAbstraction #HybridIntelligence carta.healthcare Download the transcript here

Joe Kiani is Executive Chairman at Willow Laboratories and Founder of the Patient Safety Movement Foundation.   He makes the point that the vast majority of medical harm is avoidable through the implementation of evidence-based healthcare best practices. Technology, particularly AI and remote monitoring of data from medical devices, is crucial for creating predictive models that can alert clinicians to problems and identify root causes of medical errors. The goal is to unite all healthcare stakeholders to work collaboratively toward zero preventable deaths. Joe explains, "In the US, we lose about 200,000 people a year, and about 15 times that rate is the serious harm caused by medical errors. Worldwide, we think the number is close to three million. And the reason we call it preventable is that the vast majority could be eliminated if evidence-based practices were put in place. As you can imagine, people make mistakes, and there are a lot of medical errors that may not be preventable because there is an evidence-based practice in place to avoid them. But when it comes to things like hospital-acquired infection, VTE, sepsis, failure to rescue, CLATSI, there are known evidence-based practices that, if possible, put them in place, we might get to zero, and if not zero, we'd be pretty close to zero." "Well, honestly, all patients are at risk. If you want to focus on those most at risk, we've got to miss the ones that really go wrong. If we can imagine someone going in for a simple procedure, even a cosmetic one, like a hip replacement, and the procedure goes really well." "But while there's a catheter inside the artery, someone could walk in and, without cleaning their hands, touch the patient, the bacteria could enter the bloodstream and cause a serious infection. So really, you've got to create a culture of safety where you look for ways to mitigate people's mistakes, and those are what we call evidence-based practices. There are about 20 of them, starting with cultural patient safety, on the Patient Safety Movement Foundation website that people can freely download and implement, and therefore not get into these problems." #PatientSafetyMovementFoundation #PatientSafetyMovement #PatientSafety #HealthcareQuality #ZeroHarm #EvidenceBasedPractice #AIinHealthcare #ClinicalSafety #HospitalLeadership #MedTech #CultureOfSafety #PreventableHarm #FailureToRescue #Sepsis #VTE #PatientExperience #ClinicianBurnout willowlabs.ai psmf.org Listen to the podcast here

Joe Kiani is Executive Chairman at Willow Laboratories and Founder of the Patient Safety Movement Foundation.   He makes the point that the vast majority of medical harm is avoidable through the implementation of evidence-based healthcare best practices. Technology, particularly AI and remote monitoring of data from medical devices, is crucial for creating predictive models that can alert clinicians to problems and identify root causes of medical errors. The goal is to unite all healthcare stakeholders to work collaboratively toward zero preventable deaths. Joe explains, "In the US, we lose about 200,000 people a year, and about 15 times that rate is the serious harm caused by medical errors. Worldwide, we think the number is close to three million. And the reason we call it preventable is that the vast majority could be eliminated if evidence-based practices were put in place. As you can imagine, people make mistakes, and there are a lot of medical errors that may not be preventable because there is an evidence-based practice in place to avoid them. But when it comes to things like hospital-acquired infection, VTE, sepsis, failure to rescue, CLATSI, there are known evidence-based practices that, if possible, put them in place, we might get to zero, and if not zero, we'd be pretty close to zero." "Well, honestly, all patients are at risk. If you want to focus on those most at risk, we've got to miss the ones that really go wrong. If we can imagine someone going in for a simple procedure, even a cosmetic one, like a hip replacement, and the procedure goes really well." "But while there's a catheter inside the artery, someone could walk in and, without cleaning their hands, touch the patient, the bacteria could enter the bloodstream and cause a serious infection. So really, you've got to create a culture of safety where you look for ways to mitigate people's mistakes, and those are what we call evidence-based practices. There are about 20 of them, starting with cultural patient safety, on the Patient Safety Movement Foundation website that people can freely download and implement, and therefore not get into these problems." #PatientSafetyMovementFoundation #PatientSafetyMovement #PatientSafety #HealthcareQuality #ZeroHarm #EvidenceBasedPractice #AIinHealthcare #ClinicalSafety #HospitalLeadership #MedTech #CultureOfSafety #PreventableHarm #FailureToRescue #Sepsis #VTE #PatientExperience #ClinicianBurnout willowlabs.ai psmf.org Download the transcript here

Sam Yeruva is Founder and CEO of PyCube, a company that provides software solutions to US hospitals to digitize workflows and improve operational efficiency.  He points out that many hospital processes still rely on paper, which hinders the collection of data necessary for operational intelligence and forecasting. The key to success is breaking down data silos across departments to better track assets, samples, and pharmaceuticals, improving patient care, reducing clinician burnout, and driving cost savings.  Sam explains, "PyCube is a software solutions company serving US health systems across the Continental States. We provide solutions with digitized workflows around operational efficiency of the hospitals because there are a lot of things that happen in the hospitals.  A lot of things move, a lot of patients move, a lot of samples move, assets move. There are many moving parts in service environments, such as hospitals, which are well-equipped to care for patients. We help them to digitize those workflows and be more efficient. They're hearing hospitals actually running on thin margins. We assist the hospitals to utilize technology, to be more efficient, cut down the cost, improve revenue, and do what they're supposed to do normally, which they do really well, and take care of the patients. So that's where we try to assist hospitals in adopting technology, especially AI, as it is growing these days as well."   "Operational intelligence is a term coined to mean being smarter or doing things more smartly. You'll see when you go to a hospital, most of the things are still written on pen and paper. You don't get intelligence when you don't know where things are, and you don't know where data is not flowing. So we digitize those workflows so that, first of all, you use the right tools for digitizing the workflows. And then once you have that, we will instill some intelligence into the operation as well."  #PyCube #HealthcareInnovation #HospitalOperations #DigitalHealth #WorkflowAutomation #AIinHealthcare #OperationalIntelligence #PatientSafety #NurseWorkflow #InventoryManagement #HealthIT pycube.com Listen to the podcast here

Sam Yeruva is Founder and CEO of PyCube, a company that provides software solutions to US hospitals to digitize workflows and improve operational efficiency.  He points out that many hospital processes still rely on paper, which hinders the collection of data necessary for operational intelligence and forecasting. The key to success is breaking down data silos across departments to better track assets, samples, and pharmaceuticals, improving patient care, reducing clinician burnout, and driving cost savings.  Sam explains, "PyCube is a software solutions company serving US health systems across the Continental States. We provide solutions with digitized workflows around operational efficiency of the hospitals because there are a lot of things that happen in the hospitals.  A lot of things move, a lot of patients move, a lot of samples move, assets move. There are many moving parts in service environments, such as hospitals, which are well-equipped to care for patients. We help them to digitize those workflows and be more efficient. They're hearing hospitals actually running on thin margins. We assist the hospitals to utilize technology, to be more efficient, cut down the cost, improve revenue, and do what they're supposed to do normally, which they do really well, and take care of the patients. So that's where we try to assist hospitals in adopting technology, especially AI, as it is growing these days as well."   "Operational intelligence is a term coined to mean being smarter or doing things more smartly. You'll see when you go to a hospital, most of the things are still written on pen and paper. You don't get intelligence when you don't know where things are, and you don't know where data is not flowing. So we digitize those workflows so that, first of all, you use the right tools for digitizing the workflows. And then once you have that, we will instill some intelligence into the operation as well."  #PyCube #HealthcareInnovation #HospitalOperations #DigitalHealth #WorkflowAutomation #AIinHealthcare #OperationalIntelligence #PatientSafety #NurseWorkflow #InventoryManagement #HealthIT pycube.com Download the transcript here

Professor Mark Kendall, Founder and CEO of WearOptimo, is a pioneer in micro-wearable technology and highlights the limitations of current wearables that capture only basic signals.  The WearOptimo platform uses a skin patch with painless microelectrodes to measure a range of biomarkers in the interstitial fluid just beneath the skin surface.  The company's first product is a continuous hydration monitor designed to address the widespread and under-recognized health problems caused by dehydration due to lifestyle, disease, and working conditions. Mark explains, "We are all familiar with wearables. They're everywhere these days. And when we think about wearables, we're thinking about really basic signals, like an Apple Watch, an Oura ring, or a Whoop. And they're useful for really basic things. But the challenge is that there are all manner of really important health signals out there that today's wearables, like those, are just unable to reach. So, what we're looking to tackle with our technology, our powerful platform, the micro-wearable platform, is gaining access to those key signals that today's wearables are unable to reach and really opening up genuine healthcare."   "It feels just like a sticker, as I said, but the important piece is something that's microscopic. It's microelectrodes. It's an embodiment of a field called microneedles, and I'm a founder of that field. And those microelectrodes just pierce this tough outer dead layer of skin, called the stratum corneum, and reach this location just below the skin's surface. And in that location is a rich reservoir of signals. And we measure those with bio-impedance sweeps. We pull out electrical signals from the body, and use our bespoke, novel AI model to read those signals and give us distinct health outcomes." #WearOptimo #MicroWearable #WearableTech #HealthMonitoring #HydrationHealth # #MedTech #MicroneedleTechnology #PrecisionHealth #HealthcareInnovation #DigitalHealth #Wearables #Microneedles #HydrationMonitoring #Biomarkers #PatientSafety #PerioperativeCare #OccupationalHealth #MilitaryMedicine #AIinHealthcare #EdgeComputing #PreventiveCare wearoptimo.com Listen to the podcast here

Professor Mark Kendall, Founder and CEO of WearOptimo, is a pioneer in micro-wearable technology and highlights the limitations of current wearables that capture only basic signals.  The WearOptimo platform uses a skin patch with painless microelectrodes to measure a range of biomarkers in the interstitial fluid just beneath the skin surface.  The company's first product is a continuous hydration monitor designed to address the widespread and under-recognized health problems caused by dehydration due to lifestyle, disease, and working conditions. Mark explains, "We are all familiar with wearables. They're everywhere these days. And when we think about wearables, we're thinking about really basic signals, like an Apple Watch, an Oura ring, or a Whoop. And they're useful for really basic things. But the challenge is that there are all manner of really important health signals out there that today's wearables, like those, are just unable to reach. So, what we're looking to tackle with our technology, our powerful platform, the micro-wearable platform, is gaining access to those key signals that today's wearables are unable to reach and really opening up genuine healthcare."   "It feels just like a sticker, as I said, but the important piece is something that's microscopic. It's microelectrodes. It's an embodiment of a field called microneedles, and I'm a founder of that field. And those microelectrodes just pierce this tough outer dead layer of skin, called the stratum corneum, and reach this location just below the skin's surface. And in that location is a rich reservoir of signals. And we measure those with bio-impedance sweeps. We pull out electrical signals from the body, and use our bespoke, novel AI model to read those signals and give us distinct health outcomes." #WearOptimo #MicroWearable #WearableTech #HealthMonitoring #HydrationHealth # #MedTech #MicroneedleTechnology #PrecisionHealth #HealthcareInnovation #DigitalHealth #Wearables #Microneedles #HydrationMonitoring #Biomarkers #PatientSafety #PerioperativeCare #OccupationalHealth #MilitaryMedicine #AIinHealthcare #EdgeComputing #PreventiveCare wearoptimo.com Download the transcript here

Dr. Stella Vnook, Co-Founder and Executive Chair of Kaida Biopharma, highlights the advantages for an early-stage biotech company to take a patient-centric perspective in drug development. She defines patient-centricity as focusing on whether a drug meaningfully improves a patient's life, which should influence decisions about trial design, endpoints, and side effects from the earliest stages. Kaida's work on a new treatment for ovarian cancer is designed to target tumor survival mechanisms and overcome treatment resistance, and has from the beginning taken into consideration the tolerability of treatments and the patient's quality of life. Stella explains, "We're so used to thinking drug-centric, and it's true that in the early stages of development, it's all about the molecule and the mechanism of action, and it's exciting to see how it works. But we really need to be thinking patient-centric because we will make decisions differently from the start. So it's not just about whether this drug works and how, but whether it meaningfully changes a patient's life. I think that's what patient-centric is or should be, because that would impact trial design, endpoints, and how we view tolerability or combination therapy."   "For ovarian cancer, women today may receive a variety of treatments. Now, let's talk about this for a second. It's the cancer that's usually diagnosed very late. That means the patient's tumor has already gone into the lymph nodes, and it's what we call a stage three PO4. The patients after surgery receive a variety of drugs such as platinum therapies or PARP, but they still may relapse, and they may become resistant to the therapy. Now, that initial therapy has probably had significant toxicity. Because they've become resistant to the therapy they received, now they have limited options. So fortunately, there are drugs that potentially could be eligible for FRA positive. There's been a lot of news about ELAHERE, which is great, but it's only 25% of the population, and many patients may never qualify for this treatment. So that's where Kaida comes in, because we're focusing on 80% of the population."  "Actually, the name Kaida is a dragon that eats its own tail. So that talks about the mechanism of action we've discussed: resistance. What we do is when the treatment has been given, it supports cell survival and actually eliminates the tumor's ability to replicate, which is called proliferation, causing it to destroy itself, which is called apoptosis. So in essence, the tumor disrupts itself because we're cutting off its support system." #Kaida #OvarianCancer #PatientCentric #OncologyInnovation #ProlactinReceptor #DrugDevelopment #AIinHealthcare #RealWorldEvidence #TolerabilityMatters #KaidaBiopharma #CancerCare Kaida-biopharma.com Listen to the podcast here

Dr. Stella Vnook, Co-Founder and Executive Chair of Kaida Biopharma, highlights the advantages for an early-stage biotech company to take a patient-centric perspective in drug development. She defines patient-centricity as focusing on whether a drug meaningfully improves a patient's life, which should influence decisions about trial design, endpoints, and side effects from the earliest stages. Kaida's work on a new treatment for ovarian cancer is designed to target tumor survival mechanisms and overcome treatment resistance, and has from the beginning taken into consideration the tolerability of treatments and the patient's quality of life. Stella explains, "We're so used to thinking drug-centric, and it's true that in the early stages of development, it's all about the molecule and the mechanism of action, and it's exciting to see how it works. But we really need to be thinking patient-centric because we will make decisions differently from the start. So it's not just about whether this drug works and how, but whether it meaningfully changes a patient's life. I think that's what patient-centric is or should be, because that would impact trial design, endpoints, and how we view tolerability or combination therapy."   "For ovarian cancer, women today may receive a variety of treatments. Now, let's talk about this for a second. It's the cancer that's usually diagnosed very late. That means the patient's tumor has already gone into the lymph nodes, and it's what we call a stage three PO4. The patients after surgery receive a variety of drugs such as platinum therapies or PARP, but they still may relapse, and they may become resistant to the therapy. Now, that initial therapy has probably had significant toxicity. Because they've become resistant to the therapy they received, now they have limited options. So fortunately, there are drugs that potentially could be eligible for FRA positive. There's been a lot of news about ELAHERE, which is great, but it's only 25% of the population, and many patients may never qualify for this treatment. So that's where Kaida comes in, because we're focusing on 80% of the population."  "Actually, the name Kaida is a dragon that eats its own tail. So that talks about the mechanism of action we've discussed: resistance. What we do is when the treatment has been given, it supports cell survival and actually eliminates the tumor's ability to replicate, which is called proliferation, causing it to destroy itself, which is called apoptosis. So in essence, the tumor disrupts itself because we're cutting off its support system." #Kaida #OvarianCancer #PatientCentric #OncologyInnovation #ProlactinReceptor #DrugDevelopment #AIinHealthcare #RealWorldEvidence #TolerabilityMatters #KaidaBiopharma #CancerCare Kaida-biopharma.com Download the transcript here

Dr. Deb Dittberner, Chief Clinical Officer and Director of Population Health at Herself Health, focuses on providing value-based care for women aged 50 and older through a model that prioritizes cognition, bone health, behavioral health, and cardiac health. Conventional primary care for older women often overlooks the complexities of aging, which Herself Health addresses through longer visits, proactive screening, and patient education. Technology is being successfully integrated into the environment to provide virtual visits, support medication adherence, and improve access to care.  Deb explains, "We are focusing on women 50 +, specifically women 65-plus who are heading into that Medicare world and have more complex medical problems. We see a real need to focus on that group, where we can create team-based care and deliver population health, value-based care for those patients, with a greater focus on keeping them well. And lowering healthcare costs and doctor visits by focusing on wellness rather than fee-for-service or on illness and problems."   "I think that as we age, it becomes more complicated. And I think advanced primary care takes that into consideration. We do longer visits for these patients. We focus on keeping them well. And what we're trying to do is look at the whole picture. Aging people have more hypertension, more diabetes, more chronic medical conditions, and taking the time to help with all of those conditions together and look at the whole picture is what we're trying to do." #HerselfHealth #PrimaryCare #WomensHealth #ValueBasedCare #Geriatrics #HealthcareInnovation #PatientCenteredCare #MedicareAge #ClinicalLeadership #HealthEquity #AdvancedPrimaryCare #HealthTech #PopulationHealth herself-health.com Listen to the podcast here

Dr. Deb Dittberner, Chief Clinical Officer and Director of Population Health at Herself Health, focuses on providing value-based care for women aged 50 and older through a model that prioritizes cognition, bone health, behavioral health, and cardiac health. Conventional primary care for older women often overlooks the complexities of aging, which Herself Health addresses through longer visits, proactive screening, and patient education. Technology is being successfully integrated into the environment to provide virtual visits, support medication adherence, and improve access to care.  Deb explains, "We are focusing on women 50 +, specifically women 65-plus who are heading into that Medicare world and have more complex medical problems. We see a real need to focus on that group, where we can create team-based care and deliver population health, value-based care for those patients, with a greater focus on keeping them well. And lowering healthcare costs and doctor visits by focusing on wellness rather than fee-for-service or on illness and problems."   "I think that as we age, it becomes more complicated. And I think advanced primary care takes that into consideration. We do longer visits for these patients. We focus on keeping them well. And what we're trying to do is look at the whole picture. Aging people have more hypertension, more diabetes, more chronic medical conditions, and taking the time to help with all of those conditions together and look at the whole picture is what we're trying to do." #HerselfHealth #PrimaryCare #WomensHealth #ValueBasedCare #Geriatrics #HealthcareInnovation #PatientCenteredCare #MedicareAge #ClinicalLeadership #HealthEquity #AdvancedPrimaryCare #HealthTech #PopulationHealth herself-health.com Download the transcript here

Matt Blosl, CEO of DexCare, has a core mission to help large health systems use AI responsibly to attract patients and work with them to get appropriate care. While AI's data-processing capabilities are transformative, its use in clinical recommendations remains in its early stages, constrained by fragmented data and the limited availability of validated diagnoses. Matt advises healthcare leaders to adopt a problem-first approach to AI implementation and to use technology to drive significant change rather than just incremental improvements to existing workflows. Matt explains, "Artificial intelligence is interesting. We're still in what I consider to be the Gold Rush phase of a new technology. Certainly one as disruptive as this. So I think a lot of our clients are still trying to figure out what it means. From my perspective, you said it very well. Google or the internet was kind of our first foray into providing patients more access before they even seek care or before they go in to receive care. And what I see right now is that the AI platforms are kind of the next level of that. The richness of the information is greater. And so patients are coming in more informed, and they can feel comfortable making decisions even more than they could with Google. That's clear in terms of how it's impacting the patients. I think the health systems are still trying to get their arms wrapped around what the appropriate use of AI across the enterprise is." "Now, when it comes to making treatment recommendations, I still think we're in the early stages. There are still many hallucinations. The data sources we're pulling from are still fragmented. Data hygiene and some of that data are not always accurate. So I think there's going to have to be a lot of evolution in how we manage the data and improve interoperability, so that all of the data can start to talk to one another, and we can really have a complete picture before these platforms can really impact care." #DexCare #AIinHealthcare #DigitalHealth #HealthSystems #ClinicalAI #HealthcareInnovation #PatientAccess #DigitalFrontDoor #CareOrchestration #HealthIT #Interoperability #DataQuality #PrecisionMedicine #PersonalizedCare #ClinicianExperience #HealthcareLeadership #DigitalTransformation #HealthTech #HospitalOperations #CallCenterAutomation #EmergencyMedicine dexcare.com Listen to the podcast here

Matt Blosl, CEO of DexCare, has a core mission to help large health systems use AI responsibly to attract patients and work with them to get appropriate care. While AI's data-processing capabilities are transformative, its use in clinical recommendations remains in its early stages, constrained by fragmented data and the limited availability of validated diagnoses. Matt advises healthcare leaders to adopt a problem-first approach to AI implementation and to use technology to drive significant change rather than just incremental improvements to existing workflows. Matt explains, "Artificial intelligence is interesting. We're still in what I consider to be the Gold Rush phase of a new technology. Certainly one as disruptive as this. So I think a lot of our clients are still trying to figure out what it means. From my perspective, you said it very well. Google or the internet was kind of our first foray into providing patients more access before they even seek care or before they go in to receive care. And what I see right now is that the AI platforms are kind of the next level of that. The richness of the information is greater. And so patients are coming in more informed, and they can feel comfortable making decisions even more than they could with Google. That's clear in terms of how it's impacting the patients. I think the health systems are still trying to get their arms wrapped around what the appropriate use of AI across the enterprise is." "Now, when it comes to making treatment recommendations, I still think we're in the early stages. There are still many hallucinations. The data sources we're pulling from are still fragmented. Data hygiene and some of that data are not always accurate. So I think there's going to have to be a lot of evolution in how we manage the data and improve interoperability, so that all of the data can start to talk to one another, and we can really have a complete picture before these platforms can really impact care." #DexCare #AIinHealthcare #DigitalHealth #HealthSystems #ClinicalAI #HealthcareInnovation #PatientAccess #DigitalFrontDoor #CareOrchestration #HealthIT #Interoperability #DataQuality #PrecisionMedicine #PersonalizedCare #ClinicianExperience #HealthcareLeadership #DigitalTransformation #HealthTech #HospitalOperations #CallCenterAutomation #EmergencyMedicine dexcare.com Download the transcript here

Dr. Mayank Gandhi, CEO of NEOK Bio, discusses the company's work on bispecific antibody drug conjugates and the limitations of conventional ADCs, which target a single antigen. Using a bispecific antibody to target two unique antigens on a tumor can address the shortcomings of earlier approaches by improving delivery of the toxic payload, overcoming tumor heterogeneity, and reducing off-target toxicity.  NEOK has drugs in development for prostate cancer, and lung, head, neck, and gastrointestinal tumors. The trend for ADCs is toward multi-specific and multi-payload drugs, though Mayank warns it is not a simple task to go from one to many in designing these drug conjugates. Mayank explains, "There have been a lot of advancements in the last couple of decades, and especially the last few years, in various modalities in the treatment of hematological cancers, as well as to a certain degree in solid tumors. However, for many, many solid tumors, there's still a high unmet need given the still significant outcome, poor outcomes that patients experience, particularly with patients having metastatic disease across a variety of solid tumors. Now, if you look at specific modality like ADC or antibody drug conjugates, which is where NEOK Bio is, there's been a renaissance, if you will, with this modality in the last five to six years, particularly after the approval of a drug called Enhertu, which targets HER2 mutation. Now, many ADCs have been approved with different payloads. And so definitely that's made a dent in a variety of tumors, particularly in hematological cancers and select solid tumors as well."   "Conventional ADCs thus far target one antigen or one target on a tumor. So it's an antibody-based approach. The antibody is typically pursuing one specific antigen that's usually an antigen that's expressed on tumors selectively versus normal tissue or normal cells. And then you have a linker and a payload, usually a toxic payload that's conjugated via a linker to the antibody. So that's an antibody drug conjugate construct."   "Thus far, all the ADCs approved have been targeting only one antigen with a couple of different payloads. And so our bispecific approach is targeting two different antigens. If we use a bispecific antibody that targets two unique antigens on the tumor, we have more than one place that a potential antibody can bind and deliver the toxic payload. And then we have made some very significant improvements or changes in the antibody itself." #NEOKBio #DrugDevelopment #Innovation #AntibodyDrugConjugates #ADC #Oncology #Biotech#Oncology #SolidTumors #BispecificADC #CancerResearch #TranslationalResearch #MedicalOncology #HematologyOncology #ClinicalTrials #Biotech #Pharma #DrugDevelopment #PrecisionOncology #TumorMicroenvironment #TargetedTherapy NEOKBio.com Listen to the podcast here

Dr. Mayank Gandhi, CEO of NEOK Bio, discusses the company's work on bispecific antibody drug conjugates and the limitations of conventional ADCs, which target a single antigen. Using a bispecific antibody to target two unique antigens on a tumor can address the shortcomings of earlier approaches by improving delivery of the toxic payload, overcoming tumor heterogeneity, and reducing off-target toxicity.  NEOK has drugs in development for prostate cancer, and lung, head, neck, and gastrointestinal tumors. The trend for ADCs is toward multi-specific and multi-payload drugs, though Mayank warns it is not a simple task to go from one to many in designing these drug conjugates. Mayank explains, "There have been a lot of advancements in the last couple of decades, and especially the last few years, in various modalities in the treatment of hematological cancers, as well as to a certain degree in solid tumors. However, for many, many solid tumors, there's still a high unmet need given the still significant outcome, poor outcomes that patients experience, particularly with patients having metastatic disease across a variety of solid tumors. Now, if you look at specific modality like ADC or antibody drug conjugates, which is where NEOK Bio is, there's been a renaissance, if you will, with this modality in the last five to six years, particularly after the approval of a drug called Enhertu, which targets HER2 mutation. Now, many ADCs have been approved with different payloads. And so definitely that's made a dent in a variety of tumors, particularly in hematological cancers and select solid tumors as well."   "Conventional ADCs thus far target one antigen or one target on a tumor. So it's an antibody-based approach. The antibody is typically pursuing one specific antigen that's usually an antigen that's expressed on tumors selectively versus normal tissue or normal cells. And then you have a linker and a payload, usually a toxic payload that's conjugated via a linker to the antibody. So that's an antibody drug conjugate construct."   "Thus far, all the ADCs approved have been targeting only one antigen with a couple of different payloads. And so our bispecific approach is targeting two different antigens. If we use a bispecific antibody that targets two unique antigens on the tumor, we have more than one place that a potential antibody can bind and deliver the toxic payload. And then we have made some very significant improvements or changes in the antibody itself." #NEOKBio #DrugDevelopment #Innovation #AntibodyDrugConjugates #ADC #Oncology #Biotech#Oncology #SolidTumors #BispecificADC #CancerResearch #TranslationalResearch #MedicalOncology #HematologyOncology #ClinicalTrials #Biotech #Pharma #DrugDevelopment #PrecisionOncology #TumorMicroenvironment #TargetedTherapy NEOKBio.com Download the transcript here

Louis Blankemeier, CEO and Co-Founder of Cognita, describes the significant gap between the number of radiologists and the rising volume and types of medical imaging that need to be reviewed.  The Cognita generative visual language model is an advancement over earlier radiology AI applications that were designed to flag single findings.  This integrated approach emulates a radiologist by analyzing complex images and generating full draft radiology reports, demonstrating reduced time per case, increased detection of critical findings, and decreased cognitive burden on radiologists. Louis explains, "Radiologists look at a number of different imaging types. So there are X-rays, and these are basically 2D images or 2D projections of the inside of the body. So you see all the organs superimposed on each other in a 2D image. And the radiologists have to take this 2D image and create almost a 3D representation in their head to understand what's going on in the body. They also read CT scans, which use X-ray radiation but take multiple images from different angles of the body. And then you basically reconstruct a 3D video that shows you what the inside of a body looks like. And then there are also MRI scans, which use magnetism to create a video of the inside of the body. And CT and MRI are 3D imaging modalities. So they're both kind of like videos. And you have an ultrasound, which uses sound waves, and you have a long tail of different imaging types.  But radiologist spend most of their time looking at X-rays, CT scans, and MRI images."   "A vision language model is a model that has eyes, so it can actually look at images, and then the language part describes how we are generating text in the output. And we can actually add one more descriptor to vision language. We can add the term generative. So we're actually generating text in the output of our model. We're generating the radiology report. And this is in contrast to most models out there today that are discriminative. There are these classifier models that are saying, " Is there a disease present or not? And the output is binary. It's zero one. It's not a text report in the output." #Cognita #AIinRadiology #GenerativeAI #VisionLanguageModels #RadiologyWorkflow #DiagnosticImaging #MedicalAI #HealthcareInnovation #RadiologistSupport #ClinicalDecisionSupport #PatientSafety #BurnoutReduction #FDA #BreakthroughDevice #DigitalHealth #HealthTech Cognita.ai  Listen to the podcast here

Louis Blankemeier, CEO and Co-Founder of Cognita, describes the significant gap between the number of radiologists and the rising volume and types of medical imaging that need to be reviewed.  The Cognita generative visual language model is an advancement over earlier radiology AI applications that were designed to flag single findings.  This integrated approach emulates a radiologist by analyzing complex images and generating full draft radiology reports, demonstrating reduced time per case, increased detection of critical findings, and decreased cognitive burden on radiologists. Louis explains, "Radiologists look at a number of different imaging types. So there are X-rays, and these are basically 2D images or 2D projections of the inside of the body. So you see all the organs superimposed on each other in a 2D image. And the radiologists have to take this 2D image and create almost a 3D representation in their head to understand what's going on in the body. They also read CT scans, which use X-ray radiation but take multiple images from different angles of the body. And then you basically reconstruct a 3D video that shows you what the inside of a body looks like. And then there are also MRI scans, which use magnetism to create a video of the inside of the body. And CT and MRI are 3D imaging modalities. So they're both kind of like videos. And you have an ultrasound, which uses sound waves, and you have a long tail of different imaging types.  But radiologist spend most of their time looking at X-rays, CT scans, and MRI images."   "A vision language model is a model that has eyes, so it can actually look at images, and then the language part describes how we are generating text in the output. And we can actually add one more descriptor to vision language. We can add the term generative. So we're actually generating text in the output of our model. We're generating the radiology report. And this is in contrast to most models out there today that are discriminative. There are these classifier models that are saying, " Is there a disease present or not? And the output is binary. It's zero one. It's not a text report in the output." #Cognita #AIinRadiology #GenerativeAI #VisionLanguageModels #RadiologyWorkflow #DiagnosticImaging #MedicalAI #HealthcareInnovation #RadiologistSupport #ClinicalDecisionSupport #PatientSafety #BurnoutReduction #FDA #BreakthroughDevice #DigitalHealth #HealthTech Cognita.ai Download the transcript here

Dr. Ashok Gupta, CEO and Founder of Theranow, highlights the growing demand for physical therapy and the challenges patients face in accessing care. The Theranow telehealth solution uses technologies such as computer vision and AI to enhance the effectiveness and efficiency of virtual care and to measure and document progress to support the clinician's work with the patient. Virtual physical therapy is demonstrating outcomes equal to in-person care and showing higher patient engagement and compliance, driven by the convenience of scheduling and remote monitoring tools. Ashok explains, "Physical therapy is growing with experiential growth. Means you would look at the data. It's approximately 6% to 7% a year growth going long. On top of that, not only are there requirements, but this is also like a demand-and-supply situation. If you'll just look at the other side of the data, the demand side of it, where every day, like recently, I read, it was like 10,000 people are crossing the Medicare eligibility. So every single Medicare-eligible person means there's more demand for physical therapy and rehab services."   "The physical therapists specialize in different settings or different styles of treatments. So I would say virtual care can address almost 80% of all diagnoses and 100% of all patients at any time during the injury or recovery period of rehabilitation. So we do have multiple programs. We have an ortho program for virtual care. We have a neuro program for virtual care. And then we have a pelvic health or women's health program for virtual care. So we're taking one step at a time and adding different programs. The next would be the pediatrics, and then we'll be adding that as well, slowly. So we're trying to bring in experts from each field and then make sure that our program is very tailored to the patient's needs. And then obviously it's not a traditional, conventional physical therapy that you can do." #Theranow HybridCare #PatientExperience #HealthcareAI #DigitalHealth #ClinicianWorkflow #PhysicalTherapy #Telehealth #DigitalHealth #RehabInnovation #VirtualCare #AIinHealthcare #RemotePatientMonitoring #ValueBasedCare #HealthSystems #Medicare #HealthTech #PatientEngagement #ClinicianExperience #MusculoskeletalCare Theranow.com Listen to the podcast here

Dr. Ashok Gupta, CEO and Founder of Theranow, highlights the growing demand for physical therapy and the challenges patients face in accessing care. The Theranow telehealth solution uses technologies such as computer vision and AI to enhance the effectiveness and efficiency of virtual care and to measure and document progress to support the clinician's work with the patient. Virtual physical therapy is demonstrating outcomes equal to in-person care and showing higher patient engagement and compliance, driven by the convenience of scheduling and remote monitoring tools. Ashok explains, "Physical therapy is growing with experiential growth. Means you would look at the data. It's approximately 6% to 7% a year growth going long. On top of that, not only are there requirements, but this is also like a demand-and-supply situation. If you'll just look at the other side of the data, the demand side of it, where every day, like recently, I read, it was like 10,000 people are crossing the Medicare eligibility. So every single Medicare-eligible person means there's more demand for physical therapy and rehab services."   "The physical therapists specialize in different settings or different styles of treatments. So I would say virtual care can address almost 80% of all diagnoses and 100% of all patients at any time during the injury or recovery period of rehabilitation. So we do have multiple programs. We have an ortho program for virtual care. We have a neuro program for virtual care. And then we have a pelvic health or women's health program for virtual care. So we're taking one step at a time and adding different programs. The next would be the pediatrics, and then we'll be adding that as well, slowly. So we're trying to bring in experts from each field and then make sure that our program is very tailored to the patient's needs. And then obviously it's not a traditional, conventional physical therapy that you can do." #Theranow HybridCare #PatientExperience #HealthcareAI #DigitalHealth #ClinicianWorkflow #PhysicalTherapy #Telehealth #DigitalHealth #RehabInnovation #VirtualCare #AIinHealthcare #RemotePatientMonitoring #ValueBasedCare #HealthSystems #Medicare #HealthTech #PatientEngagement #ClinicianExperience #MusculoskeletalCare Theranow.com Download the transcript here

Dr. Javier Szwarcberg, CEO of Spruce Biosciences,  is developing drugs for rare diseases with a primary focus on Sanfilippo Syndrome Type B, a devastating genetic neurodegenerative disease affecting children.  The source of this condition is a lack of an enzyme, which results in a buildup of a toxic substance in the brain.  The company's drug is an enzyme replacement therapy administered directly to the brain to bypass the blood-brain barrier, and clinical trial data is showing a strong effect on the toxic substrate in the brain and a meaningful benefit on cognition. Javier explains, "It's a devastating, profoundly affecting disease whereby children are typically born normally and born asymptomatic. And over time, they develop an accumulation of a toxic substrate throughout the body, but primarily the brain. And because of that, it eventually results in a fairly young age, usually between two and a half and I would say three and a half, in symptoms starting. That toxic substance builds in throughout the brain and starts affecting initially learning behavior. Sleep patterns are very much affected, whereby children don't sleep at night and sleep during the day, and they're very hyperactive. And sometimes the diagnosis is confused, and there's no clarity as to what is going on with the child, early in the onset of the disease."   "Yes, it's a genetic disease that's inherited. There's a missing enzyme responsible for the metabolism of this toxic substrate, which I talked about, called heparan sulfate. So when heparan sulfate builds up in the brain, it causes inflammation and neurotoxicity, ultimately resulting in neurodegeneration. Think about it as a disease that is very similar to what you end up seeing with Alzheimer's, whereby the toxic substrate in Alzheimer's is between neurons and outside of the actual cell. In this case, in this disease, the toxic substance, which is different than the one that accumulates in Alzheimer's but builds within the neural cells. Yes, so that's very well-known and very well-characterized." #SpruceBio #SanfilippoSyndrome #MPSIIIB #CureSanfilippo #RareDiseases #EnzymeReplacementTherapy #LysosomalStorageDisorders #BiopharmaceuticalInnovation #ClinicalTrials #RareDiseaseResearch #HealthcareInnovation #PrecisionMedicine sprucebio.com Listen to the podcast here

Dr. Javier Szwarcberg, CEO of Spruce Biosciences,  is developing drugs for rare diseases with a primary focus on Sanfilippo Syndrome Type B, a devastating genetic neurodegenerative disease affecting children.  The source of this condition is a lack of an enzyme, which results in a buildup of a toxic substance in the brain.  The company's drug is an enzyme replacement therapy administered directly to the brain to bypass the blood-brain barrier, and clinical trial data is showing a strong effect on the toxic substrate in the brain and a meaningful benefit on cognition. Javier explains, "It's a devastating, profoundly affecting disease whereby children are typically born normally and born asymptomatic. And over time, they develop an accumulation of a toxic substrate throughout the body, but primarily the brain. And because of that, it eventually results in a fairly young age, usually between two and a half and I would say three and a half, in symptoms starting. That toxic substance builds in throughout the brain and starts affecting initially learning behavior. Sleep patterns are very much affected, whereby children don't sleep at night and sleep during the day, and they're very hyperactive. And sometimes the diagnosis is confused, and there's no clarity as to what is going on with the child, early in the onset of the disease."   "Yes, it's a genetic disease that's inherited. There's a missing enzyme responsible for the metabolism of this toxic substrate, which I talked about, called heparan sulfate. So when heparan sulfate builds up in the brain, it causes inflammation and neurotoxicity, ultimately resulting in neurodegeneration. Think about it as a disease that is very similar to what you end up seeing with Alzheimer's, whereby the toxic substrate in Alzheimer's is between neurons and outside of the actual cell. In this case, in this disease, the toxic substance, which is different than the one that accumulates in Alzheimer's but builds within the neural cells. Yes, so that's very well-known and very well-characterized." #SpruceBio #SanfilippoSyndrome #MPSIIIB #CureSanfilippo #RareDiseases #EnzymeReplacementTherapy #LysosomalStorageDisorders #BiopharmaceuticalInnovation #ClinicalTrials #RareDiseaseResearch #HealthcareInnovation #PrecisionMedicine sprucebio.com Download the transcript here

Zach Shultz, Senior Director of Product Policy and Solutions at EnableComp, describes the challenges of revenue cycle management in healthcare with a focus on the strategic importance of full-time equivalent (FTE) allocation.  Hospitals could improve their bottom line by outsourcing complex, low-reimbursement claims, such as those from the VA so that in-house staff can focus on higher-value commercial claims. Despite the emergence of AI as a significant factor in automating the review process, human intervention is irreplaceable for quality assurance, managing escalations, and resolving complex claims. Zach explains, "I think that, especially serving the post- COVID landscape that we exist in today, staffing has become a kind of delicate thing. If you think about the rate posts or during the post-pandemic period, it was really hard to staff revenue cycle offices or staff business in general. Now, you kind of fast-forward to 2026, and maybe it's not as difficult as it was, but I think hospitals and businesses want to make sure they're very precise and strategic in how they utilize resources."   "Obviously, keeping overhead at a manageable level is really important to growth and success. So I think it's an invariable value that should always be discussed, particularly when it gets into the complex claims space, as we do. The work comps, the VAs, and claim types like that may take or require a little bit more manual intervention. It's super important to determine whether it's worth taking on these things myself or if outsourcing them is justified so I can focus on things that maybe have a slightly higher yield."  #EnableComp #RevenueCycleManagement #RCM #HealthTech #FTEEfficiency #ComplexClaims #RCMTechnology #HealthcareRCM #RevenueCycle #HealthcareFinance #StaffingStrategy #HealthcareOperations #AIinHealthcare #WorkforceOptimization #HealthcareLeadership #PatientFinancialServices enablecomp.com Listen to the podcast here